Agile Therapeutics Inc (AGRX) Receives Average Recommendation of “Buy” from Analysts
Agile Therapeutics Inc (NASDAQ:AGRX) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8.25.
A number of brokerages have recently commented on AGRX. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price target on shares of Agile Therapeutics in a report on Thursday, September 21st. HC Wainwright set a $10.00 price target on Agile Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. Royal Bank of Canada reissued a “buy” rating and set a $10.00 price target on shares of Agile Therapeutics in a report on Wednesday, October 18th. Finally, William Blair cut Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 26th.
A number of hedge funds have recently made changes to their positions in AGRX. Franklin Resources Inc. boosted its stake in Agile Therapeutics by 39.2% during the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after purchasing an additional 82,213 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Agile Therapeutics in the 2nd quarter valued at $309,000. Royal Bank of Canada boosted its position in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of Agile Therapeutics in the 2nd quarter valued at $205,000. 72.92% of the stock is owned by institutional investors and hedge funds.
Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. equities analysts anticipate that Agile Therapeutics will post -0.97 EPS for the current fiscal year.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.